Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Vor Bio announced completion of enrollment in its Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis, with topline results expected in 1H27. The company expanded into ocular myasthenia gravis with a new Phase 3 trial and continues enrollment in primary Sjögren's disease. With $481.6 million in cash, the company projects runway into early 2029. Additional data from the TELIGAN trial showed telitacicept demonstrated durable kidney function preservation in IgA nephropathy.